Pancreatic Cancer Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Pancreatic Cancer Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

October 12
21:41 2022
Pancreatic Cancer Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Pancreatic Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Pancreatic Cancer Pipeline Report

  • DelveInsight’s Pancreatic Cancer Pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Pancreatic Cancer treatment.
  • The leading Pancreatic Cancer Companies includes FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee’s Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie,  Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, and others are developing potential drug candidates to improve the Pancreatic Cancer treatment scenario.
  • The promising Pancreatic Cancer therapies in the pipeline includes FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, ACP-196, Demcizumab, Galunisertib, Antroquinonol, NC-6004, Evofosfamide, and others
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD), and Fast Track designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
  • CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first-in-class globally. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on GC/GEJ and PC. CT041 has demonstrated promising therapeutic efficacy and favorable safety in ongoing clinical trials. CARsgen believes that CT041 has the potential to become a backbone therapy for GC/GEJ and PC in the future and benefit a large population of patients worldwide. Currently, it is in Phase I/II stage of clinical trial evaluation to treat pancreatic cancer.

 

Get an overview of the Pancreatic Cancer Pipeline landscape @ Pancreatic Cancer Pipeline Outlook

 

Pancreatic Cancer Overview

Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas).

Patients with adenocarcinoma of pancreas typically present with painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor. Weight loss occurs in about 90% of patients. Abdominal pain occurs in about 75% of patients. Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine. Sometimes, patients may present with recurrent deep vein thrombosis (DVT) due to hypercoagulability that prompts clinicians to suspect cancer and a full workup of cancer. If adenocarcinoma of the pancreas is suspected, multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease, including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability.

 

Latest Breakthroughs and Developments in the Pancreatic Cancer Treatment Landscape

  • In August 2021, Aravive announced that the company had dosed the first patient in the Phase Ib portion of its Phase Ib/II trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. The Phase Ib portion of the clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel.
  • In July 2021, Novartis announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD), and Fast Track designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD
  • NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling. NGM initiated a Phase 2 randomized, single-blind (investigator-blinded), placebo-controlled, multi-center expansion study (PINNACLES) in March 2021 to evaluate NGM120 as a first-line treatment in 60 patients with metastatic pancreatic cancer. In the ongoing study, patients will be randomized to either NGM120 or placebo in combination with gemcitabine/Nab-paclitaxel. The study will evaluate the effects of NGM120 on both cancer and cancer-related cachexia.

 

Pancreatic Cancer Emerging Drugs

  • Pamrevlumab: FibroGen
  • Niraparib: Innovent Biologics
  • CT041: CARsgen Therapeutics
  • APG-1387: Ascentage Pharma
  • NGM120: NGM Biopharmaceuticals

 

Get to know more information about Pancreatic Cancer treatment @ Pancreatic Cancer Clinical Trials

 

Pancreatic Cancer Pipeline Therapeutics Analysis

There are approx. 120+ key companies which are developing therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

 

DelveInsight’s Pancreatic Cancer Pipeline Report covers around 150+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Discover more about therapy set to grab substantial Pancreatic Cancer Pipeline landscape @ Pancreatic Cancer Market Drivers and Barriers

 

Scope of the Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Pancreatic Cancer Companies- FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee’s Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie,  Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, and others.
  • Pancreatic Cancer Therapies– FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, ACP-196, Demcizumab, Galunisertib, Antroquinonol, NC-6004, Evofosfamide, and others
  • Pancreatic Cancer Therapeutic Assessment by Product Type
  • Pancreatic Cancer Therapeutic Assessment by Stage and Product Type
  • Pancreatic Cancer Therapeutic Assessment by Route of Administration
  • Pancreatic Cancer Therapeutic Assessment by Stage and Route of Administration
  • Pancreatic Cancer Therapeutic Assessment by Molecule Type
  • Pancreatic Cancer Therapeutic Assessment by Stage and Molecule Type
  • Pancreatic Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  • Pancreatic Cancer – Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Mid Stage Products (Phase II)
  10. Niraparib: Innovent Biologics
  11. Early Stage Products (Phase I/II)
  12. CT041: CARsgen Therapeutics
  13. Preclinical and Discovery Stage Products
  14. ONC 212: Oncoceutics
  15. Inactive Products
  16. Pancreatic Cancer Key Companies
  17. Pancreatic Cancer Key Products
  18. Pancreatic Cancer- Unmet Needs
  19. Pancreatic Cancer- Market Drivers and Barriers
  20. Pancreatic Cancer- Future Perspectives and Conclusion
  21. Pancreatic Cancer Analyst Views
  22. Pancreatic Cancer Key Companies
  23. Appendix

 

Got Queries? Reach out for more information on the Pancreatic Cancer Pipeline Report- Pancreatic Cancer Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories